A Phase I/II Open Label Multi Center Study of Immune Checkpoint Therapy With Nivolumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2019 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 30 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Sep 2018.
- 20 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium